We aim to become the leading international advanced therapeutics company for human muscle and to bring regenerative cell and gene therapies into widespread clinical practice.
Within the next five years, we will establish platforms based on original and engineered muscle stem cell therapeutics targeting specific muscle diseases and bring the first advanced muscle regenerative therapies to market.
At MyoPax, we are proud of our
• patented method for the production of human satellite-derived muscle stem cells (PhSats) with their regenerative phenotype and unmatched purity
• gmp-compliant manufacturing process
• preclinical data that validates the regenerative efficacy of PHSats
• state-of-the-art mRNA-based CRISPR/Cas gene editing tool set for the treatment of muscular dystrophies
• scientific and medical expertise in muscle diseases
• strong affiliation with and vocal support for patient networks
• dedicated team of recognized experts
Join us! Let’s combine our strengths to restore muscle power to those who need it.